Communiqués EXACT Therapeutics

Actions

EXTX

NO0010852213

Recherche biotechnologique et médicale

PEA

PEA/PME

Marché Fermé - Oslo Bors 16:45:00 14/08/2026			Varia. 5j.	Varia. 1 janv.
0,6900 ^NOK	-1,43 %		-8,00 %	-50,00 %

30/06	Exact Therapeutics se retirera d'Euronext Growth Oslo en octobre	MT
26/06	EXACT Therapeutics AS reçoit un avis de sécurité favorable pour la dose de 60 µl/kg dans le cadre de l'essai de phase 2 ENACT	RE

Communiqués

02/07	EXACT Therapeutics : Oslo Stock Exchange approves application to delist EXACT Therapeutics’ shares	PU
30/06	EXACT Therapeutics AS - Removal from trading	AQ
26/06	EXACT Therapeutics: Positive second safety read-out from the Phase 2 ENACT trial in pancreatic cancer	PU
12/06	EXACT Therapeutics minutes from Annual General Meeting June 12, 2026	AQ
04/06	EXACT Therapeutics - webcast presentation	AQ
01/06	EXACT Therapeutics: Announces webcast regarding strategic intent to delist the company's shares from listing on Euronext Growth, Oslo	AQ
29/05	EXACT Therapeutics - Notice for Annual General Meeting 2026	AQ
29/05	EXACT Therapeutics: Strategic intent to delist the company's shares from listing on Euronext Growth, Oslo	AQ
09/04	EXACT Therapeutics : Annual Report 2025	PU
26/03	EXACT Therapeutics AS: Share capital increase registered	AQ
13/03	EXACT Therapeutics AS - Minutes from extraordinary general meeting on 13 March 2026	AQ
13/03	EXACT Therapeutics : Notice of Extraordinary General Meeting for EXACT Therapeutics March 13, 2026	PU
03/03	EXACT Therapeutics : First patient dosed in Europe in Phase 2 trial in patients with locally advanced pancreatic cancer	PU
03/03	EXACT Therapeutics : First patient dosed in Europe in Phase 2 trial in patients with locally advanced pancreatic cancer	PU
27/02	EXACT Therapeutics AS: Notice of extraordinary general meeting	AQ
27/02	EXACT Therapeutics AS: Warrants exercise	AQ
11/02	EXACT Therapeutics: Investor presentation for the global investor call regarding the ongoing warrants exercise program	PU
06/02	EXACT Therapeutics: Global investor call regarding the ongoing warrants exercise program	AQ
05/02	EXACT Therapeutics: Correction of final warrants exercise date	AQ
05/02	EXACT Therapeutics: Warrants exercise by leading shareholders and primary insiders	AQ
05/02	EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB	AQ
27/01	EXACT Therapeutics: Positive initial safety read-out from the Phase 2 ENACT trial in pancreatic cancer, triggering option to exercise warrants	AQ
27/01	EXACT Therapeutics : Positive initial safety read-out from the Phase 2 ENACT trial in pancreatic cancer, triggering option to exercise warrants	PU
27/01	EXACT Therapeutics: Positive initial safety read-out from the Phase 2 ENACT trial in pancreatic cancer, triggering option to exercise warrants	PU
08/01	EXACT Therapeutics' Phase 2 trial in pancreatic cancer patients to be presented at the 2026 ASCO Gastrointestinal Cancers Symposium	AQ